Vonolend Tablet
Vonoprazan
20 mg
Ziska Pharmaceuticals Ltd.
| Pack size | 30's pack |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 10.00 AED |
Available as:
Indications
Vonolend Tablet is used for:
Reflux oesophagitis, Peptic ulcer disease, Gastric ulcer, Duodenal ulcer, Eradication of H. pylori associated with peptic ulcer disease, Prophylaxis of NSAID-induced ulcers
Adult Dose
Oral
Reflux oesophagitis
Adult: 20 mg once daily for 4 weeks, may be followed by a further 4 weeks if necessary.
Maintenance therapy of healing in patients with repeat recurrence or relapse: 10 mg once daily, may be increased to 20 mg once daily if needed.
Gastric ulcer
Adult: 20 mg once daily for 8 weeks.
Duodenal ulcer
Adult: 20 mg once daily for 6 weeks.
Prophylaxis of NSAID-induced ulcers
Adult: Including cases that occur during low-dose aspirin therapy: 10 mg once daily.
Eradication of H. pylori associated with peptic ulcer disease
Adult: Adjunct in the triple therapy regimen with antibiotics: 20 mg bid for 7 days in combination with amoxicillin and clarithromycin.
Alternatively, 20 mg bid may be given for 7 days in combination with amoxicillin and metronidazole.
Impaired Hepatic Function
Vonoprazan should be administered with care in patients with hepatic disorders as a delay in the metabolism and excretion of Vonoprazan may occur, which may result in an
increase in the concentration of Vonoprazan in the blood. Hepatic function abnormalities including liver injury have been reported. Discontinuation of Vonoprazan is
recommended in patients who have evidence of liver function abnormalities or if they develop signs or symptoms suggestive of liver dysfunction.
Child Dose
Renal Dose
Vonoprazan should be administered with care in patients with renal disorders as a delay in the excretion of Vonoprazan may occur, which may result in an increase in the concentration of Vonoprazan in the blood.
Administration
May be taken with or without food.
Contra Indications
Lactation. Concomitant use with atazanavir and rilpivirine.
Precautions
May mask symptoms of gastric malignancy. Renal and hepatic impairment. Pregnancy.
Evaluate the type of ulcer to rule out gastric malignancy before treatment initiation. Monitor Mg levels.
Pregnancy-Lactation
Pregnancy
Vonoprazan should be used in pregnant women or women having the possibility of being pregnant only if the expected therapeutic benefit is thought to outweigh any possible risk.
Lactation
It is advisable to avoid the administration of Vonoprazan to nursing mothers. However, when the administration is indispensable, nursing should be discontinued.
Interactions
May increase blood concentration with CYP3A4 inhibitors (e.g. clarithromycin) and amoxicillin in the triple treatment for H. pylori eradication. May enhance the effects of digoxin and methyldigoxin. May diminish the effects of nelfinavir, itraconazole, and tyrosine kinase inhibitors (e.g. gefitinib, nilotinib).
Potentially Fatal: May significantly decrease the blood concentrations of atazanavir and rilpivirine.
Adverse Effects
Side effects of Vonoprazan :
Significant: Clostridioides difficile-associated infection, pseudomembranous colitis, increased intragastric pH, benign gastric polyps (prolonged use); increased risk of hip, spine, or wrist osteoporosis-related fractures (long-term use or high doses); hepatic function abnormalities, including liver injury. Rarely, hypomagnesaemia (prolonged use).
Gastrointestinal disorders: Diarrhoea, constipation, nausea, abdominal distention or discomfort, stomatitis, taste abnormality.
Hepatobiliary disorders: Jaundice.
Immune system disorders: Hypersensitivity reactions (e.g. urticaria, anaphylactic shock).
Investigations: Increased AST, ALT, and gamma-glutamyl transferase.
Skin and subcutaneous tissue disorders: Rash, Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, drug eruption.
Mechanism of Action
Vonoprazan is a potassium-competitive acid blocker (PCAB). It competitively inhibits the binding of K ions to hydrogen/potassium-adenosine triphosphate (H+/K+-ATPase) enzyme system that acts as the proton pump of the gastric parietal cell, thereby inhibiting gastric acid production.
Note
Vonolend 20 mg Tablet manufactured by Ziska Pharmaceuticals Ltd.. Its generic name is Vonoprazan. Vonolend is availble in Bangladesh.
Farmaco BD drug index information on Vonolend Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.